Phathom Pharmaceuticals annual working capital
2018
2019
2020
2021
2022
2023
2024
2025
Phathom Pharmaceuticals Working Capital Growth & History (PHAT)
Phathom Pharmaceuticals's working capital was $96.9M for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $96.9M | −$177.5M | −64.68% |
| 2024 | 2024-12-31 | $274.4M | −$84.2M | −23.49% |
| 2023 | 2023-12-31 | $358.7M | $224.4M | +167.10% |
| 2022 | 2022-12-31 | $134.3M | −$33.3M | −19.89% |
| 2021 | 2021-12-31 | $167.6M | −$68.2M | −28.93% |
| 2020 | 2020-12-31 | $235.8M | −$16.0M | −6.36% |
| 2019 | 2019-12-31 | $251.9M | $253.1M | — |
| 2018 | 2018-12-31 | −$1.3M | — | — |
Phathom Pharmaceuticals quarterly working capital
Q4.18
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $142.1M | $15.1M | +11.87% |
| Q1 2026 | 2026-03-31 | $151.5M | −$39.3M | −20.61% |
| Q4 2025 | 2025-12-31 | $96.9M | −$177.5M | −64.68% |
| Q3 2025 | 2025-09-30 | $114.7M | −$193.9M | −62.84% |
| Q2 2025 | 2025-06-30 | $127.1M | −$130.7M | −50.71% |
| Q1 2025 | 2025-03-31 | $190.9M | −$106.0M | −35.70% |
| Q4 2024 | 2024-12-31 | $274.4M | −$84.2M | −23.49% |
| Q3 2024 | 2024-09-30 | $308.5M | $105.8M | +52.18% |
| Q2 2024 | 2024-06-30 | $257.8M | $21.6M | +9.15% |
| Q1 2024 | 2024-03-31 | $296.9M | $171.5M | +136.73% |
| Q4 2023 | 2023-12-31 | $358.7M | $224.4M | +167.10% |
| Q3 2023 | 2023-09-30 | $202.7M | $27.8M | +15.90% |
| Q2 2023 | 2023-06-30 | $236.2M | $48.0M | +25.50% |
| Q1 2023 | 2023-03-31 | $125.4M | −$8.9M | −6.66% |
| Q4 2022 | 2022-12-31 | $134.3M | −$33.3M | −19.89% |
| Q3 2022 | 2022-09-30 | $174.9M | −$22.6M | −11.43% |
| Q2 2022 | 2022-06-30 | $188.2M | $16.5M | +9.58% |
| Q1 2022 | 2022-03-31 | $134.3M | −$67.6M | −33.48% |
| Q4 2021 | 2021-12-31 | $167.6M | −$68.2M | −28.93% |
| Q3 2021 | 2021-09-30 | $197.5M | −$2.0M | −1.00% |
| Q2 2021 | 2021-06-30 | $171.7M | −$63.7M | −27.06% |
| Q1 2021 | 2021-03-31 | $202.0M | −$55.3M | −21.49% |
| Q4 2020 | 2020-12-31 | $235.8M | −$16.0M | −6.36% |
| Q3 2020 | 2020-09-30 | $199.5M | $329.3M | — |
| Q2 2020 | 2020-06-30 | $235.4M | — | — |
| Q1 2020 | 2020-03-31 | $257.3M | — | — |
| Q4 2019 | 2019-12-31 | $251.9M | $253.1M | — |
| Q3 2019 | 2019-09-30 | −$129.8M | — | — |
| Q4 2018 | 2018-12-31 | −$1.3M | — | — |
Phathom Pharmaceuticals working capital trends
Over the last five fiscal years, Phathom Pharmaceuticals's working capital decreased from $235.8M to $96.9M, a change of −$138.9M. The latest reported quarter, Q2 2026, shows $142.1M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals source filings ↗Community posts
Phathom’s Voquezna growth narrows its quarterly loss and supports positive operating cash flow
Phathom Pharmaceuticals ($PHAT) reported third-quarter 2026 revenue of $84.7 million, up 71% from a year earlier and 14% from the preceding quarter. Cumulative Voquezna prescriptions surpassed two million, reflecting continued adoption of t ...
Phathom’s Voquezna exclusivity dispute expands with FDA consultation and another challenger
Phathom ($PHAT) said the FDA opened a public docket seeking comment on legal and regulatory questions raised by a challenge to Voquezna’s exclusivity. Comments are due by November 23. Phathom has also moved to intervene in BDR Pharmaceutica ...
